A-Alpha Bio was founded in 2017 by a group of current and former synthetic biology doctorate students at the University of Washington Institute for Protein Design and Center for Synthetic Biology.
The company's technology is called AlphaSeq. It is a platform technology that measures protein interactions by quantifying interactions between cells displaying proteins on their surfaces. It uses engineered yeast cells to understand how drugs interact with different proteins. The technology helps pharmaceutical companies understand how potential drug candidates would operate inside a person's body, letting them rule out problematic drugs before they start clinical trials.
In July 2018 the company announced it had won a $225,000 grant from the National Science Foundation (NSF). The funding brings the company's total funds raised to date to $410,000.
Co-founder and CEO
Documentaries, videos and podcasts